Clinical Trial Update: A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating MP0250 in combination with bortezomib and dexamethasone for relapsed multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• MP0250

Snippet

Sponsor: Molecular Partners AG | Conditions: Multiple Myeloma in Relapse | Phase 1, Phase 2 | Status: COMPLETED